Government builds database of every drug supply chain—citing national security.

What it does

This bill requires the federal government to maintain a list of essential medicines critical to national security and public health, assess vulnerabilities in their supply chains (especially dependence on foreign suppliers), and create a system to map and monitor pharmaceutical supply chains using data analytics. The Department of Health and Human Services coordinates the effort with the Department of Defense and other agencies, and must report regularly to Congress on supply chain risks and mitigation strategies.

Why we flagged it

The bill's core function is to map, assess, and monitor vulnerabilities in the supply chains of essential medicines, with explicit focus on national security risks and foreign dependence. It is a supply-chain transparency and resilience measure, not a price control, access expansion, or market intervention.

What the text implies

• The bill's focus on medicines sourced from or dependent on China may trigger or accelerate reshoring of pharmaceutical manufacturing, with significant capital investment and cost implications for drugmakers—potentially raising drug prices in the short term.
• The requirement to map supply chains and share data among federal agencies creates a centralized government database of pharmaceutical manufacturing locations and production volumes, which could be used for future price controls, production mandates, or export restrictions.
• The Defense Production Act authority referenced in Section 3 is not invoked by this bill but is flagged as a mitigation tool; future administrations could use supply chain data collected here to justify DPA orders forcing domestic production or price controls.
• The bill exempts information sharing from certain confidentiality laws (Section 7) but preserves trade-secret status under other statutes—creating ambiguity about what data is truly protected and what may eventually be disclosed to Congress or the public.
• Annual reporting requirements to Congress on supply chain vulnerabilities may create political pressure to restrict imports or mandate domestic production, even when economically inefficient.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens public health and national security by identifying and addressing vulnerabilities in the supply of critical medicines—particularly those at risk of shortage or dependent on foreign sources. Citizens benefit from reduced risk of medicine shortages during emergencies and greater transparency about supply chain vulnerabilities, though the bill does not directly lower drug prices or expand access.

Who stands to gain

• domestic pharmaceutical manufacturers (potential reshoring incentives)
• advanced manufacturing technology providers
• pharmaceutical supply chain consulting firms
• cybersecurity firms (infrastructure protection contracts)

Named in the bill

Department of Health and Human Services, Department of Defense, Office of the Director of National Intelligence, Senate Committee on Armed Services, Senate Committee on Health, Education, Labor, and Pensions, Senate Committee on Homeland Security and Governmental Affairs, House Committee on Armed Services, House Committee on Energy and Commerce, House Committee on Homeland Security, Defense Production Act of 1950, Executive Order 13944, 21st Century Cures Act — and 2 more

Where it stands

7 cosponsors: 4 Republicans, 2 Democrats, 1 Independents.

• May 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 15, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 12 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,500,000 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Gary Peters, the sponsor, reported $-186,100 in PAC receipts in the 2026 cycle.

• Phlow Corporation — $780,000 on 2 filings
• Association for Clinical Oncology — $600,000 on 2 filings
• The United States Pharmacopeial Convention — $350,000 on 3 filings
• Vizient Inc — $320,000 on 1 filing
• American Society of Health-system Pharmacists — $250,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.